Clinical Trial Update: Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab and tazemetostat to overcome immune tolerance after ASCT or CAR-T therapy in patients with aggressive B-cell non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: Northwestern University | Conditions: B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING